Introduction {#Sec1}
============

Atherogenesis is a chronic and evolving inflammatory process. Many theories have been proposed to explain the initiation and progression of the atheromatous plaque from the asymptomatic "raised fatty streak or intimal xanthoma" and proatheroma (types II and III lesions respectively_AHA classification) to the formation of the symptomatic and obstructive complicated fibroatheroma (type VI lesion_AHA classification). During the formation of these plaques, a critical primary step is the accumulation and oxidation of low-density lipoprotein (LDL) particles. Oxidized-LDL favours leukocyte recruitment and activation as well as cell death, which leads to the generation of complex atherosclerotic plaques \[[@CR2]\]. These high-risk atherosclerotic plaques have a particular phenotype that is characterized by a high content of necrotic core, a thin inflamed fibrous cap (due to intense accumulation of macrophages) and the scarce presence of smooth muscle cells. Within the necrotic core, underlying the thin fibrous cap, hemorrhage, calcification and intraplaque vasa vasorum are frequently found \[[@CR3], [@CR4]\].

IVUS and IVUS-based imaging modalities have the potential to be able to provide useful insights into the different phases of the development of the plaque, as well as the different key players in this process (i.e. components of the plaque such as necrotic core). In this review, we will discuss the capabilities and limitations of IVUS-based tissue characterization imaging modalities in providing this information.

Plaque type characterization {#Sec2}
============================

Detection of calcification {#Sec3}
--------------------------

On IVUS, calcium appears as bright echoes with acoustic shadowing. Dense calcium obstructs the penetration of ultrasound Fig. [1](#Fig1){ref-type="fig"}. As a consequence, IVUS detects only the leading edge of calcium and therefore cannot determine its thickness. Calcification on IVUS is usually described by its circumferential angle (arc), longitudinal length and depth. Calcification can be located deeper in the arterial wall or at the surface of the plaque, in close contact with the lumen wall interface, and can produce reverberations or repeated reflections at reproducible distances. IVUS has shown a significantly higher sensitivity than fluoroscopy in the detection of coronary calcification. \[[@CR5]\] As compared to histology, virtual histology has a predictive accuracy of 96.7% in the detection of dense calcium \[[@CR6]\] (Fig. [1](#Fig1){ref-type="fig"}).Fig. 1Cross sections of IVUS and corresponding VH-IVUS frames characterizing a calcified plaque. *Grey* scale IVUS has both a high sensitivity and specificity in the detection of calcium. Calcium usually obstructs the penetration of ultrasound and consequently obscures the imaging of the underlying vascular wall; this phenomenon is known as acoustic shadowing (*thin white arrows* in the top panel). The corresponding IVUS virtual histology frames are shown at the bottom of the figure with the dense calcium being shown in *white*. The *grey*scale image is reconstructed from the amplitude of the signal whereas with virtual histology, the underlying radiofrequency data is used for tissue characterization as illustrated

Arterial remodeling and plaque composition {#Sec4}
------------------------------------------

Arterial remodeling refers to a continuous process involving changes in vessel size as measured by the EEM cross-sectional area; this is also known as the vessel cross-sectional area---CSA. "Positive remodeling" occurs when there is an outward increase in EEM and "negative remodeling" occurs when the EEM decreases in size (i.e. shrinkage of the vessel) \[[@CR7]\]. The magnitude and direction of remodeling can be expressed by following index: EEM cross-sectional area at the plaque site divided by EEM CSA at the reference "non-diseased" vessel site. Positive remodeling demonstrates an index \>1.05 whilst negative remodelling has an index \<0.95. Direct evidence of remodeling can only be demonstrated in serial studies showing changes in the EEM CSA over time, since remodeling may also occur at the "normal-appearing" reference coronary segment \[[@CR7]\]. The limitations of coronary angiography in determining disease burden and stenosis severity are largely due to the effects of vessel remodeling. Pathological studies have also suggested a potential relationship between positive vessel remodeling and plaque vulnerability. Vessels with positive remodeling have shown an increase in inflammatory marker concentrations, larger lipid cores, paucity of smooth muscle cells and medial thinning \[[@CR8]--[@CR10]\]. Several IVUS studies have linked positive vessel remodelling with culprit \[[@CR11]\] and ruptured coronary plaques \[[@CR12], [@CR13]\]. Positive remodelling has also been observed more often in patients with acute coronary syndromes than in those with stable coronary artery disease \[[@CR14], [@CR15]\], and has been identified as an independent predictor of major adverse cardiac events in patients with unstable angina \[[@CR16]\]. Plaques exhibiting positive remodelling also more often have evidence of thrombus and signs of rupture \[[@CR17]\]. The patterns of remodelling have also been correlated with plaque composition; soft plaques are associated with positive remodelling whilst fibrocalcific plaques are more often associated with negative or constrictive remodelling \[[@CR18]\]. Similar findings have been observed in studies utilizing IVUS virtual histology analyses, a technique developed specifically for tissue characterization; positive remodelling was found to directly correlate with the presence and size of necrotic core, and was inversely associated with the presence of fibrotic tissue \[[@CR19]\].

Vulnerable plaque and thrombi {#Sec5}
-----------------------------

Acute coronary syndromes are often the first manifestation of coronary atherosclerosis, making the identification of plaques at high-risk of complications an important component of strategies to reduce casualties associated with atherosclerosis. Our current understanding of plaque biology suggests that \~60% of clinically evident plaque rupture originates within an inflamed thin-capped fibroatheroma \[[@CR20], [@CR21]\]. Pathological studies have demonstrated that ruptured plaques are mainly located in the proximal portions of the LAD and LCX and are more disperse within the RCA \[[@CR22]\]. This tendency of advanced plaques to preferentially develop in these locations has been explained by the low shear stress conditions generated in areas with tortuosity or many branches. Low shear stress may induce the migration of lipid and monocytes into the vessel wall, which may lead to further progression of the lesion towards a plaque with high risk of rupture \[[@CR23]\].

The definition of an IVUS-derived TCFA is a lesion fulfilling the following criteria in at least 3 frames: (1) plaque burden ≥40%; (2) *confluent* necrotic core ≥10% in direct contact with the lumen (i.e. no visible overlying tissue) \[[@CR24]\]. By using this definition of IVUS-derived TCFA, in patients with ACS who underwent IVUS of all three epicardial coronaries, on average 2 IVUS-derived thin cap fibroatheromas were found per patient with half of these patients showing evidence of outward remodelling. \[[@CR24]\].

Hong et al. \[[@CR25]\] reported the frequency and distribution of TCFA identified by virtual histology intravascular ultrasound in acute coronary syndrome (ACS = 105 pts) and stable angina pectoris (SAP = 107 pts) in a 3-vessel IVUS-VH study. The findings showed that there were 2.5 ± 1.5 TCFAs per patient with ACS and 1.7 ± 1.1 TCFAs per patient with SAP, *P* \< 0.001. The presentation of ACS was the only independent predictor for multiple ID-TCFA (*P* = 0.011). 83% of ID-TCFAs were located within 40 mm of the proximal coronary artery.

The potential value of these VH IVUS-derived plaque types to predict adverse coronary events was evaluated in an international multicentre prospective study, the Providing Regional Observations to Study Predictors of Events in the Coronary Tree study (PROSPECT study) \[[@CR26]\].

The PROSPECT trial was a multi-center, natural history study of acute coronary syndrome patients. All patients underwent PCI to their culprit lesion at baseline, followed by an angiogram and IVUS virtual histology of all three major coronary arteries. One of the main findings was that a TCFA, with a minimum lumen area of ≤4 mm^2^, and a large plaque burden (≥70%), had a 17.2% likelihood of causing a future event within three years \[[@CR26]\]. Interestingly, the anticipated higher frequency of acute thrombotic cardiovascular events did not occur, with only a 1% rate of myocardial infarction and no deaths directly attributable to non-culprit vessels over a period of 3 years follow-up. These results suggest that non-culprit obstructive coronary plaques were more likely to be associated with increasing anginal symptoms rather than thrombotic acute events, with 8.5% of patients presenting with worsening angina and 3.3% with unstable angina.

Plaque ruptures occur at sites of significant plaque accumulation, but are often not highly stenotic, as defined by coronary angiography due to positive vascular remodeling \[[@CR12], [@CR13], [@CR27]\]. The transition to plaque rupture has been characterized by the presence of active inflammation (monocyte and macrophage infiltration), thinning of the fibrous cap (\<65 μm), development of a large lipid necrotic core, endothelial denudation with superficial platelet aggregation and intraplaque hemorrhage \[[@CR28]\]. The remaining plaques that can cause ACS contain calcium nodules (\~10%) or have none of the pathological features described above (\~20%). Superficial plaque erosion can explain at least a portion of the latter events, particularly in women and diabetics \[[@CR29]\]. The lack of a cellular or anatomical signature of plaque erosion can make it difficult for existing imaging methods to have a high accuracy in predicting future ACS events. In addition, most plaque ruptures are frequently clinically silent; the occurrence of repetitive healed plaque ruptures may contribute to the progression of stable coronary disease into obstructive disease \[[@CR30]\].

Ruptured plaques may have a variable appearance on IVUS. Most commonly, IVUS may reveal an "axial", abrupt ulceration depicted as an echolucent "void" or cavity beginning at the luminal-intimal border. These features should be distinguished from a longitudinal tear of the intima and media associated with spontaneous or iatrogenic dissection. The tear of the rupture in the fibrous cap can be identified in approximately 60% of the cases and occurs more often at the shoulder of the plaque than in the centre \[[@CR12], [@CR31], [@CR32]\]. Due to its relatively poor resolution, IVUS is unsuitable to detect a thin fibrous cap. However, IVUS often reveals other features of ruptured plaques which are large in volume, eccentric, have mixed or soft composition and irregular surface, and are associated with expansive remodelling \[[@CR12], [@CR13], [@CR33], [@CR34]\]. Ruptured plaques have been shown to have quantitatively less calcium, especially superficial calcium, but a larger number of small (\<90º arc) calcium deposits, particularly deep calcium deposits \[[@CR35]\]. IVUS can also reveal blood speckles passing through intra-plaque channels created by the rupture. These usually produce a typical hazy, complex with non stenotic angiographic appearances of the ruptured plaques.

Several IVUS studies have reported the frequency and distribution of plaque ruptures during investigation of the three coronary epicardial vessels. Rioufol et al. studied 24 patients (72 arteries) with ACS and found a mean prevalence of two ruptured plaques per patient. Interestingly, 12.5% of these patients had ruptured plaques in the three major coronary arteries. Only 37.5% of the ruptured plaques were located at the culprit lesion, and 79% of the patients also had a ruptured plaque located somewhere other than at the culprit lesion \[[@CR36]\]. In a similar study in 45 patients with acute myocardial infarction (AMI), plaque rupture was observed in 21 patients (47%) at the culprit site and 17 additional plaque ruptures were found at remote sites in 11 patients (24%) \[[@CR37]\]. Hong et al., evaluated the incidence of plaque rupture depending on the clinical presentation. They performed 3-vessel IVUS examination in 235 patients (122 AMI and 113 stable angina pectoris---SAP). Plaque rupture of infarct-related or target lesions occurred in 66% of AMI patients and in 27% of SAP patients. Non-infarct-related or non-target artery plaque ruptures occurred in 17% of AMI patients and 5% of SAP patients. Multiple plaque ruptures were observed in 20% of AMI and 6% of SAP patients \[[@CR38]\]. The same authors evaluated the distribution of plaque rupture in native coronary arteries in 392 patients (231 ACS and 161 SAP). Three-vessel IVUS imaging showed that plaque ruptures occurred mainly in the proximal segments of the LAD (83% of LAD ruptured plaques), the proximal and distal segments of the RCA (48 and 32% of RCA ruptured plaques, respectively), and the entire LCX \[[@CR39]\]. These results are in line with another study that included 104 patients and studied 160 ruptured plaques in the LAD, the majority of plaque ruptures were located within the proximal 30 mm of the artery \[[@CR40]\].

A study aimed at characterizing plaque ruptures in the left main coronary artery (LMCA) found 16 plaque ruptures in 17 patients (2 AMI, 13 unstable angina and 1 SAP). The ruptures were located in the distal portion and/or bifurcation of the LMCA, often did not compromise the lumen, and had an angiographic complex appearance. When ruptured plaques involved the bifurcation LAD-LCX, they often occurred opposite to the flow divider \[[@CR41]\]. This is in line with findings made by our group; lesions involving the bifurcation LAD-LCX were predominantly located in the outer wall of the carina, and such locations were often associated with a larger necrotic core content \[[@CR42]\].

Ruptured atherosclerotic plaques in native coronary arteries are well described with intravascular ultrasound; they are however, not well described in saphenous vein grafts (SVGs). In 791 pre-intervention IVUS SVG studies, 95 ruptured plaques in 76 SVGs (73 patients) were identified (prevalence of 9.7%). These ruptured plaques were found to be associated with complex angiographic characteristics and expansive remodelling \[[@CR43], [@CR44]\]. Likewise, in an analysis of 300 ruptured plaques in SVGs in 254 patients, Maehara et al., demonstrated that ruptured plaques, as detected by IVUS, strongly correlated with a complex angiographic lesion morphology: ulceration in 81%, intimal flap in 40%, thrombus in 7%, and aneurysm in 7% \[[@CR12]\].

IVUS has also been used to assess the natural evolution of ruptured plaques. IVUS studies have suggested that up to 50% of the ruptured plaques detected in a first ACS event heals with medical therapy, without a significant change in plaque size \[[@CR45]\]. One study revealed complete healing of plaque rupture in 29% of patients treated with statins and incomplete healing in untreated patients \[[@CR46]\].

The ruptured plaque profile in 40 patients referred for cardiac catheterization has previously been described \[[@CR47]\]. In total, there were 13 patients with stable angina, 12 with unstable angina, and 15 with acute myocardial infarction. Ruptured plaque was identified in 26 patients and, as expected, was more frequent in patients with acute myocardial infarction and unstable angina. Patients with ruptured plaques were found to have a larger body mass index, were more likely to be smokers and had more diffuse calcification and necrotic core areas when compared to those patients without plaque rupture. Of note, is that the location of plaque ruptures in this study mirrored the pathological findings \[[@CR48]\]. In a study performed by our group, the proximal left anterior descending coronary artery was the most common site of plaque rupture. In a pathological series of 79 ruptures, Burke et al. \[[@CR48]\] found 74% of the plaque ruptures occurred in the proximal left anterior descending artery.

Similarly, in a report by Hong et al., the frequency and distribution of ruptured plaques identified by IVUS-VH in acute coronary syndrome (ACS = 105 pts) and stable angina pectoris (SAP = 107 pts) in a 3-vessel IVUS-VH study were reported. \[[@CR25]\] 76 ruptured plaques (55 in ACS and 21 in SAP) were described with the presentation of ACS being the only independent predictor for multiple plaque ruptures (*P* = 0.013).

Although plaque characteristics do not yet influence current therapeutic guidelines, the available clinical imaging modalities, IVUS and IVUS-based tissue characterization techniques such as virtual histology, integrated basckscattered IVUS and iMap, have the ability to identify some of the pathological atheroma features described above (Fig. [2](#Fig2){ref-type="fig"}).Fig. 2Examples of VH-IVUS images classified by a two-dimensional lesion analysis. (IMT) intimal medial thickening; (PIT) pathological intimal thickening; (FT) fibrotic plaque; (FC) fibrocalcific plaque; (FA) fibroatheroma and (caFA) calcified fibroatheroma; (VH-TCFA) Virtual Histology-thin cap fibroatheroma and (VH-caTCFA) Virtual Histology-calcified thin cap fibroatheroma. Reprinted from EuroIntervention Vol 5, number 2, Garcia-GArcia HM et al. Tissue characterisation using intravascular radiofrequency data analysis: recommendations for acquisition, analysis, interpretation and reporting. Pages 186. Copyright (2009), with permission from Europa Edition

*Thrombus* represents the ultimate pathological feature leading to ACS. Thrombus is usually recognized as an echolucent intraluminal mass, often with a layered or pedunculated appearance by IVUS \[[@CR7]\]. Fresh or acute thrombus may appear as an echodense intraluminal tissue, which does not follow the circular appearance of the vessel wall, whilst older, more organized thrombus has a darker ultrasound appearance. However, none of these IVUS features are a hallmark for thrombus, and one should consider slow flow (fresh thrombus), air, stagnant contrast or black hole, an echolucent neointimal tissue observed after DES and radiation therapy, as differential diagnoses \[[@CR7]\].

None of the IVUS-based imaging modalities available can reliably identify thrombus.

Assessment of progression/regression of coronary atherosclerosis {#Sec6}
================================================================

Quantification of atheroma or plaque area in cross-sectional IVUS images is performed by subtracting the lumen area from the EEL area. Hence, IVUS defined atheroma area is a combination of plaque plus media area. The atheroma area can be calculated in each frame (cross-sectional image), and total atheroma volume (TAV) can be calculated based on pullback speed during imaging acquisition. Atheroma volume can be reported as the percent of the volume of the external elastic membrane occupied by atheroma namely percent atheroma volume (PAV). Parameters commonly used to report the extent of the coronary atherosclerosis are shown in (Fig. [3](#Fig3){ref-type="fig"}).Fig. 3Parameters commonly used to report the extent of the coronary atherosclerosis are total atheroma volume (TAV) and percent atheroma volume (PAV). EEM, external elastic membrane; CSA, cross-sectional area

Measurements are performed between the inner lumen border and the media, delineated by the IEL, which corresponds to the "true" histological area of the atheroma. Intravascular imaging has played an important role in the understanding of atherosclerosis disease in humans and translation of novel therapies to the clinical arena.

Drug effects on atherosclerosis {#Sec7}
-------------------------------

The initial observations about a expansive continuous relationship between coronary heart disease risk and blood cholesterol levels led to the conduction of a number of IVUS-based studies to evaluate the effectiveness of differing lipid lowering drugs on atheroma size. Changes in plaque characteristics may be a more relevant endpoint to predict the risk of vascular thrombosis than plaque progression or regression of mild to moderate disease. Imaging tools to accurately evaluate plaque characteristics were not available until recently. Other limitations of using conventional grayscale IVUS to assess the natural history of atherosclerosis should be enumerated: (1) Catheterization, which is an invasive procedure, is required for serial imaging; (2) only a segment of the coronary tree can be studied; (3) plaque composition is not obtained; (4) there is no direct evidence linking changes in coronary plaques and clinical events.

The efficacy of lowering LDL-C with inhibitors of hydroxymethylglutaryl coenzyme A reductase (statins) is unequivocal; however the change in atheroma size by statins is not constant across all IVUS studies. There are many potential explanations for these discrepancies in IVUS studies, such as drug properties, dose, and duration of treatment. Other medications have been studied with IVUS greyscale and IVUS derived imaging modalities (Table [1](#Tab1){ref-type="table"}).Table 1Intravascular ultrasound progression/regression studies (published with permission of European Heart Journal)StudyDesignYearTreatment*n*FUPrimary endpointResults (mean ± SD)Statin trials GAIN \[[@CR49]\]RCT2001Atorvastatin4812 monthsPlaque volume2.5 ± 24.9 mm^3^Control5111.8 ± 31 mm^3^ ESTABLISH \[[@CR50]\]RCT2004Atorvastatin246 months% change in plaque volume13.1 ± 12.8%Control248.7 ± 14.9% REVERSAL \[[@CR51]\]RCT2004Atorvastatin25318 months% change in plaque volume4.1 ± 29.6%Pravastatin2495.4 ± 20.1% Jensen \[[@CR52]\]Observational2004Simvastatin4012 months% change in plaque volume6.30% Petronio \[[@CR53]\]RCT2005Simvastatin3612 monthsPlaque volume−2.5 ± 3.0 mm^3^/mmControl351.0 ± 3.0 mm^3^/mm Nishioka \[[@CR54]\]Observational2004Pravastatin, atorvastatin, simvastatin and fluvastatin226 monthsPlaque Volume30.9 ± 15.6 mm^3^Control2635.5 ± 12.7 mm^3^ Tani \[[@CR55]\]RCT2005Pravastatin526 months% change in plaque volume−14.4 ± 23%Control231.1 ± 4.6% ASTEROID \[[@CR56]\]Observational2006Rosuvastatin34924 monthsChange in PAV−0.98 ± 3.15% Takashima \[[@CR57]\]Observational2007Pitavastatin416 months% change in plaque volume−10.6 ± 9.4%Control418.1 ± 14.0% COSMOS \[[@CR58]\]Observational2009Rosuvastatin12618 monthsChange in PAV−5.1 ± 14.1% JAPAN-ACS \[[@CR59]\]RCT2009Atorvastatin1278--12 months% change in plaque volume−18.1 ± 14.2%Pitavastatin125−16.9 ± 13.9% HirayamaObservational2009Atorvastatin2828 weeks% change in plaque volume−9.4 ± 10.3%80 weeks−18.9 ± 14.1%ACAT (acyl coenzyme A: cholesterol acyltransferase) inhibitor trials A-PLUS \[[@CR60]\]RCT2004Avasimibe 50 mg10824 monthsChange in PAV0.7 ± 0.4%Avasimibe 250 mg980.8 ± 0.4%Avasimibe 750 mg1171.0 ± 0.3%Placebo1090.4 ± 0.4% ACTIVATE \[[@CR61]\]RCT2006Pactimibe20618 monthsChange in PAV0.69 ± 0.25%Placebo202−0.59 ± 0.25%Increasing high-density lipoprotein therapies ApoA-I Milano \[[@CR62]\]RCT2003ApoA-I Milano 15 mg/kg215 weeksChange in PAV−1.29 ± 3.5%ApoA-I Milano 45 mg/kg15−0.73 ± 2.8%Placebo110.14 ± 3.09% ERASE \[[@CR63]\]RCT2007CSL-111 (reconstituted HDL infusion)894 weeks% change in plaque volume−3.41 (IQR, −6.55--2.25)Placebo47−1.62 (IQR, −5.95--1.94) CART-2 \[[@CR64]\]RCT2008Succinobucol (AGI-1067)18312 monthsAbsolute change in plaque volume−3.4 ± 14.5 mm^3^Placebo49−0.6 ± 13.4 mm^3^Others therapies CAMELOT \[[@CR65]\]RCT2004Amlodipine9124 monthsChange in PAV0.5 ± 3.9%Enalapril880.8 ± 3.7%Placebo951.3 ± 4.4% WasedaObservational2006Losartan417 monthsChange in plaque area−9.9 ± 3.1 mm^2^Non ARB237 months−9.1 ± 2.7 mm^2^ ILLUSTRATE \[[@CR66]\]RCT2007Torcetrapib + atorvastatin46424 monthsChange in PAV0.12 ± 2.99%Atorvastatin4460.19 ± 2.83% PERSPECTIVE \[[@CR67]\]RCT2007Perindopril7536 monthsChange in plaque area−0.2 ± 1.6mm^2^Placebo69−0.1 ± 1.2 mm^2^ PERISCOPE \[[@CR68]\]RCT2008Pioglitazone,17918 monthsChange in PAV−0.16% (95% CI, −0.57--0.25%)Glimepiride1810.73% (95% CI, 0.33--1.12%) STRADIVARIUS \[[@CR69]\]RCT2008Rimonabant33518 monthsChange in PAV0.25% (95% CI, −0.04--0.54%)Placebo3410.51% (95% CI, 0.22--0.80%) ENCORE II \[[@CR70]\]RCT2009Nifedipine9718--24 months% change in plaque volume5.0 (95% CI, −1.3, 11.2)Placebo963.2 (95% CI,-1.9, 8.3) APPROACH \[[@CR71]\]RCT2010Rosiglitazone23318 monthsChange in PAV−0.21 (95% CI, −0.86, 0.44)Glipizide2290.43 (95% CI, −0.22, 1.08)IVUS-based tissue characterization studies Yokoyama \[[@CR72]\]RCT2005Atorvastatin256 monthsOverall plaque size and tissue characterization by IB IVUSAtorvastatin reduced plaque size and changed plaque compositionControl25 Kawasaki \[[@CR73]\]RCT2005Pravastatin,176 monthsOverall tissue characterization by IB IVUSStatins reduced lipid without changes in plaque sizeAtorvastatin18Diet17 IBIS 2 \[[@CR74]\]RCT2008Darapladib17512 monthsNecrotic core vol by IVUS VHDarapladid reduced significantly necrotic corePlacebo155 Nasu \[[@CR75]\]Observational2009Fluvastatin4012 monthsOverall tissue characterization by IVUS VHFluvastatin reduced plaque volume and fibro-fattyControl40 Hong \[[@CR76]\]RCT2009Simvastatin5012 monthsOverall tissue characterization by IVUS VHBoth reduced necrotic core and increased in fibro-fatty volumeRosuvastatin50 Toi \[[@CR77]\]RCT2009Atorvastatin802--3 weeksOverall tissue characterization by IVUS VHPitavastatin reduced plaque volume and fibro-fattyPivastatin80 Miyagi \[[@CR78]\]Observational2009Statin (pravastatin, pitavastatin, atorvastatin, fluvastatin, simvastatin)446 monthsOverall tissue characterization by IB IVUSStatins reduced lipid and increased fibrousNon statin56*IVUS* intravascular ultrasound, *IB* integrated backscatter, *VH* virtual histology

Nevertheless, no single report has been described showing a clear and direct association between reduction in plaque size, composition and/or plaque type with the reduction in clinical events. This is in part due to the fact that clinical outcome studies are expensive, since they have to include a large population (that should be imaged in at least at 2 different time points) that have to be followed up for a prolonged period of time in order to ensure the required number of events have occurred (which are becoming scarce due to the improvements in standards of care) in order to best assess the treatment effect.

Bill D. Gogas has received grant support from the Hellenic Heart Foundation.

**Open Access** This article is distributed under the terms of the Creative Commons Attribution Noncommercial License which permits any noncommercial use, distribution, and reproduction in any medium, provided the original author(s) and source are credited.

**Conflict of interest** None.
